what the literature says

A New Scientific Consensus

Compared to an obsolete standard of care that emphasizes anatomical disease alone, the detection and treatment of ischemia is vital in properly treating patients suffering from ischemic heart disease (IHD).

The ISCHEMIA Trial
“There was no significant correlation between severity of ischemia and severity of nonobstructive atherosclerosis on CCTA ... This suggests that atherosclerosis may not be the main contributor to ischemia in these patients.”
The FAME Trial
"It has been known for decades that the most important prognostic factor among patients with coronary artery disease is the presence and extent of inducible ischemia."
The FAME 2 Trial
“Among patients with stenoses that were not functionally significant, the best available medical therapy alone resulted in an excellent outcome, regardless of the angiographic appearance of the stenoses.”
The COURAGE Trial
“Thus, unstable coronary lesions that lead to myocardial infarction are not necessarily severely stenotic, and severely stenotic lesions are not necessarily unstable.”
The CorMicA Trial
“Our study ... highlights the limitations of anatomical coronary artery imaging. These tests have limited sensitivity for diagnosing disorders of coronary vascular function.”
The WISE Trial
“1 in 3 of the deaths in this cohort occurred in women without obstructive CAD, a condition often considered benign and without guideline-recommended treatments ... These women were most often not treated.”

Ischemia Often Exists Beyond
The Major Arteries

Coronary microvascular dysfunction, a subset of diseases affecting the microvasculature of the heart, has not proven to be benign, and the scientific community now recognizes the importance of interrogating the entire coronary circulation, including the microvasculature, to understand cardiac function.
Unfortunately for impacted patients, it's also clear that clinical practice is only beginning to catch up.
50.2%
had seen 3 or more cardiologists for treatment.
77.8%
of patients were told that their symptoms were not cardiac.
42.1%
of patients were prescribed an anti-depressant.
34.4%
lived with symptoms for 3 or more years before diagnosis.
66.4%
were told they would not die or have a heart attack.
Unquestionable Impact on Patient Prognosis

The diagnostic process and prognosis for these patients suspected of ischemia with no obstructed coronary arteries (INOCA) is measurably worse when compared to otherwise healthy patients.

The Evolving Role of Coronary Microvascular Dysfunction from CMD patients.

50-65%
of INOCA patients are believed to have CMD
4x increase
in mortality
5x increase
in major adverse cardiac events (MACE)
14%
of all acute MIs present with non-obstructive coronary artery disease
the current state of care

The Clinical Reality of Addressing IHD

Angina and anginal equivalents remain common complaints among patients, but increasingly, functionally significant coronary lesions are not being found within the catheterization lab.

Our current standard of care, primarily focused on identifying angiographic evidence of obstructive epicardial disease, regrettably results in a significant number of "inconclusive" or "intermediate" findings in symptomatic patients.

Unlock An ischemia-first paradigm

The Diagnostic Landscape for IHD

Far too often, our care pathways treat patients based on our own clinical limitations, instead of the latest findings in clinical literature. Nowhere is that more the case than in our current clinical approach to ischemia.

Stress EKG
Stress Echo
MCG
Nuclear Stress
Invasive CA
REQUIREMENTS

Time to Perform

1 hour

1 hour

90 sec

2 hours

2 hours

Time to Result

Hours

Hours

5 min

Hours

Hours

Stress Required?

Yes

Yes

No

Yes

No

Radiation?

None

Medium

None

High

High

Recurring Costs

Low

Medium

None

High

High

Operator Certification?

Yes

Yes

Specialized Operator

Yes

Yes

Patient Prep?

High

High

Low

High

High

Req. Disease Burden

High

High

Low

Medium

Low

The Clinical Challenge, Summarized.

Detecting functionally significant ischemia is important, but doing so in clinical practice isn't always easy.

"Patients don't want to be on all these medications if they don't have a disease that needs that...diagnosing CMD is critical and based on the data we got from our pilot work, MCG may play a role in that pathway, as an early-on test."

Odayme Quesada, MD

MD, MHS, FACC, FAHA Medical Director, The Christ Hospital Women’s Heart Center